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Abstract: Various signal transduction pathways seem to be involved in chemoresistance mechanism of glioblasto-
mas (GBMs). miR-21 is an important oncogenic miRNA which modulates drug resistance of tumor cells. We ana-
lyzed the expression of 5 miRNAs, previously found to be dysregulated in high grade gliomas, in 9 pediatric (pGBM) 
and in 5 adult (aGBM) GBMs. miR-21 was over-expressed, with a significant difference between pGBMs and aGBMs 
represented by a 4 times lower degree of expression in the pediatric compared to the adult series (p = 0.001). Doxo-
rubicin (Dox) seems to be an effective anti-glioma agent with high antitumor activity also against glioblastoma stem 
cells. We therefore evaluated the chemosensitivity to Dox in 3 GBM cell lines (A172, U87MG and T98G). Dox had a 
cytotoxic effect after 48 h of treatment in A172 and U87MG, while T98G cells were resistant. TUNEL assay verified 
that Dox induced apoptosis in A172 and U87MG but not in T98G. miR-21 showed a low basal expression in treated 
cells and was over-expressed in untreated cells. To validate the possible association of miR-21 with drug resistance 
of T98G cells, we transfected anti-miR-21 inhibitor into the cells. The expression level of miR-21 was significantly 
lower in T98G transfected cells (than in the parental control cells). Transfected cells showed a high apoptotic rate 
compared to control after Dox treatment by TUNEL assay, suggesting that combined Dox and miR-21 inhibitor 
therapy can sensitize GBM resistant cells to anthracyclines by enhancing apoptosis.
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Introduction 
Glioblastoma multiforme (GBM) is one of the 
most lethal forms of brain tumor, with 5-year 
survival rates ranging from 5% to 10%. Pediatric 
GBMs are often associated with distinct cyto-
genetic and molecular alterations, which differ 
from those observed in the more common adult 
counterparts. Relatively few molecular studies 
have been performed on pediatric GBM chemo-
resistance, with somewhat conflicting results 
[1-5].
MicroRNAs (miRNAs) are endogenous single-
stranded RNA molecules that constitute a novel 
class of gene regulators, and are involved in the 
control of cell differentiation, proliferation, apo- 
ptosis, anti-viral defense and cancer. Recent 
studies have shown deregulation of miRNA 
expression in various tumor types [6-9], demon-
strating also a fundamental role in tumor pro-
gression and invasion [10]. They also seem to 
modulate drug sensitivity/resistance of the 
tumor cells [11].
Alterations in miRNA expression levels are 
associated with a number of neural diseases 
[12-15] and brain tumors [16-18]. Recently, 
specific miRNA expression profiles have been 
identified in GBMs [17, 18], but there are only 
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limited data on the role of miRNA in pediatric 
GBM [19, 20].
miR-21 is an important oncogenic miRNA that 
promotes cell invasion, by regulating multiple 
genes, including PTEN, RECK and MARCKS, in 
several types of cancers, such as glioma, ovar-
ian epithelial carcinoma and prostate cancer 
[21-23].
miR-21 overexpression in human breast cancer 
is associated with advanced clinical stage, 
lymph node metastasis and poor prognosis 
[24], and its dysregulation plays a critical role in 
Doxorubicin (Dox) resistance of  breast cancer 
via targeting PTEN [25].
Therefore, investigation of mir-21 expression 
profile can be useful to determine whether it is 
involved in determining the chemotherapy 
response of brain tumors. 
In the present study we investigated the expres-
sion pattern of a set of 5 miRNAs (miR-21, miR-
7, miR-124, miR-137 and miR-128) that are 
specifically over- or under-expressed in high 
grade glioma cells [18, 26] in a series of 9 pedi-
atric GBMs (pGBMs) and 4 adult GBMs (aGBMs) 
and in three glioblastoma cell lines (U87MG, 
A172, T98G). Since miR-21 was found to be 
over-expressed, we investigated its potential 
role in the response to Dox treatment in an in 
vitro GBM model.
Materials and methods 
Patients 
All patients with GBM (WHO-grade IV) seen 
between 2008 and 2013 at the Meyer 
Children’s University Hospital in Florence were 
eligible for this study. Histological diagnosis 
and tumor grading were carried out based on 
2007-World Health Organization (2007-WHO) 
criteria [27]. The study was approved by the 
institutional Ethical Committee. Informed con-
sent was obtained from the parents or legal 
guardians in all cases. Nine patients were 
enrolled in the study. Their main clinical charac-
teristics are summarized in Table 1. Diagnosis 
was confirmed by the review of the CNS nation-
al panel of pathologists. Median age at the time 
of diagnosis was 8 ± 4.6 years (range, 1-15 
years). All had been treated with chemotherapy 
and/or radiotherapy according to current front-
line therapeutic studies of the Associazione 
Italiana Ematologia Oncologia Pediatrica 
(AIEOP). All underwent surgery for resection of 
disease, which turned to be complete in 3 of 9 
cases. The median follow up was 10 ± 6.1 
months (range, 3-24 months).
Five adult GBM samples were obtained by the 
Pathology Unit of the Careggi University Hos- 
pital in Florence.
Cell lines
Three human GBM cell lines, A172, U87MG and 
T98G, were employed in this study (American 
Type Culture Collection; ATCC). U87MG and 
T98G were grown in Eagle’s Minimum Essential 
Medium, while A172 was grown in Dulbecco’s 
Modified Eagle Medium. Each medium was 
supplemented with 10% fetal bovine serum 
and 1% penicillin-streptomycin. All cell lines 
were maintained in a humidified atmosphere of 
5% CO2-95% air at 37°C. Cells from exponen-
tially growing cultures were used for all experi- 
ments.
Table 1. Clinical characteristics of pediatric Glioblastoma Multiforme (pGBM)
ID Gender Age at diagnosis (years) Surgery First-line Treatment Response FU (months) Status
P1 F 12 PTR TMZ + RT PR 8 DOD
P2 F 1 GTR HDCT - RT CR 14 DOD
P3 M 9 PTR Vinorelbine + RT PR 12 DOD
P4 F 1 GTR HDCT + RT CR 24 DOD
P5 M 4 PTR HDCT - RT PR 3 DOD
P6 F 8 PTR Vinorelbine + RT PR 19 DOD
P7 M 15 PTR Vinorelbine + RT PR 8 DOD
P8 M 12 By TMZ + RT PR 7 DOD
P9 F 7 PTR TMZ + RT PR 10 DOD
GTR: gross total removal; PTR: partial total removal; By: biopsy; HDCT: high-dose chemotherapy; RT: radiotherapy; TMZ: temo-
zolomide; CR: complete response; PR: partial response; FU: follow-up; AWD: alive with disease; DOD: dead of disease.
miRNA expression profiles in pediatric glioblastoma multiforme
233 Am J Cancer Res 2015;5(1):231-242
Drug
Doxorubicin (Adriblastina 50 mg) was obtained 
from commercial sources (Pfizer) and tested at 
various plasma peak concentrations (PPC; 10×, 
1×, and 0.1× PPC) [28] for miRNA expression 
studies. Doses of 0.1 and 0.5 µg/ml were used 
for MTT and TUNEL assay. The drug was pre-
pared immediately prior to use.
In vitro drug assay
U87MG, A172 and T98G cell lines were seeded 
in a volume of 3 ml at 1 × 105 cells/well in 
6-well plates, allowed to adhere for 24 hours 
and subsequently exposed to the drug for 12, 
24 and 48 hours. The following Dox concentra-
tions were used: 8.34 μg/ml for T98G and 
U87MG, and 0.834 μg/ml for A172. Untreated 
cells were used as a negative control. All experi-
ments were conducted in triplicate.
Expression study
miRNAs were extracted with RecoverAllä Total 
Nucleic Acid Isolation (Ambion) from paraffin-
embedded tissues (3-5 slices of tissue with a 
thick ≥ 10 μm) and with mirVanaä miRNA 
Isolation Kit (Ambion) from pellets of cell lines. 
miR-21, miR-7, miR-124, miR-137 and miR-128 
expression levels were determined using com-
mercial assays (Assay on demand, Applied 
Biosystems)  on a 7700 ABI PRISM Sequence 
Detector (Applied Biosystems). 
Real-Time PCR was performed on cDNAs syn-
thesized using the TaqManâ MicroRNA Reverse 
Transcription Kit (Applied Biosystems). All ass- 
ays were performed in triplicate. For each 
miRNA, the expression levels, normalized to 
RNU48 (Applied Biosystems), were calculated 
using 2-∆∆Ct [29]. Adult and pediatric GBMs 
were subsequently normalized compared to 
FirstChoice® Human Brain Reference Total 
(Life Technologiesä). The expression results in 
pGBMs were also compared with those from a 
sample of pediatric non-tumoral cerebral cor-
tex processed with the same experimental pro-
cedure, whereas the treated cell lines were nor-
malized compared to the corresponding untre- 
ated cells.
MTT assay
Cytotoxicity was measured using the MTT assay 
(in vitro toxicology assay kit MTT based, Sigma). 
The key component of this assay is (3-[4,5- 
dimethylthiazol-2yl]-2,5-diphenyl tetrazolium 
bromide), a yellow salt that mitochondrial dehy-
drogenases of viable cells convert into purple 
formazan crystals, whose concentration is 
measured spectrophotometrically. We have 
conducted preliminary experiments to deter-
mine the best seeding concentration for 
U87MG, T98G and A172. Consequently, cells 
were seeded at the following densities: A172, 6 
× 104 cells/well, U87MG, 4 × 104 cells/well and 
T98G, 2 × 104 cells/well in 24-well plates. After 
24 hours, the cells were treated with 0.1 and 
0.5 µg/ml Dox for 24 and 48 hours. The MTT 
assay was performed following the manufac-
turer’s instructions. The plates were placed on 
a shaker for 10 min to enhance solubilization of 
the precipitate. The absorbance (OD) of each 
well was then measured on a MULTISKAN FC 
(Thermo Scientific) microplate reader at a test 
wavelength of 550 nm. All experiments were 
performed in triplicate.
TUNEL assay
Apoptotic cells were detected by the terminal 
deoxynucleotidyl-transferase-mediated dUTP 
nick end-labeling (TUNEL) assay using in situ 
cell death detection kit, fluorescein (Roche). 
The best seeding concentration was preliminar-
ily established at the following densities: A172, 
18 × 104 cells/well, U87MG, 18 × 104 cells/
well, and T98G, 3 × 104 cells/well in 6-well 
plates containing cover slips. After 24 hours, 
the cells were treated with 0.1 and 0.5 µg/ml 
Dox for 30 hours. After treatment, the cover 
slips were washed three times with PBS 1% and 
fixed in 4% paraformaldehyde solution for 30 
minutes at room temperature. Then, cells were 
permeabilized by using sodium citrate 0.1%, 
TRITON × 100 0,1% for 5 min on ice. Finally, the 
TUNEL assay was performed, following the 
manufacturer’s instructions. The results were 
analyzed by fluorescence microscopy (Leitz, 
Type 307-148002, Wetzlar, Germany), equipped 
with E4 and N2.1 filters (Leica, Milan, Italy) 
using an oil immersion 100× magnification 
objective. Images were captured by a Canon 
digital camera using Remote Capture software 
(provided by Canon, Japan). All experiments 
were performed in triplicate.
miR-21 inhibition
Anti-miR-21 (AMI17000, id No. AM10206) was 
introduced into T98G cells at a final concentra-
tion of 10, 30, 60, 90, 120, 160 nM [30]. T98G 
cells were plated in 24-well plates (2 × 104 
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cells/well) and transfected 48 hours later using 
LipofectamineTM RNAi Max Transfection Agent 
(Invitrogen). The lowest possible concentration 
that achieved the most significant inhibition 
was chosen as the optimal dosage. Cells were 
transfected with the optimal dosage of 60 nM. 
To study the concomitant effects of miR-21 
inhibition and Dox, cells were seeded into 6 
well-plates at 4 × 104 cells/well and then trans-
fected with anti-miR-21 at 60 nM, with or with-
out Dox treatment at 0.5 µg/ml, for 72 hours 
[30].
MTT analysis on T98G cells transfected with 
anti-miR-21
T98G cells transfected with anti-miR-21 at 60 
nM were subjected to MTT assay. Cells were 
seeded into 24 well-plates at 3 × 104 cells/well, 
transfected with anti-miR-21 at 60 nM for 24 
hours and then treated with Dox. MTT analysis 
was performed after 72 hours of Dox treat-
ment, following the manufacturer’s instruc-
tions. The OD of each well was measured on a 
MULTISKAN FC (Thermo Scientific) microplate 
reader at a test wavelength of 550 nm. All 
experiments were performed in triplicate.
TUNEL analysis on T98G cells transfected with 
anti-miR-21
T98G cells transfected with anti-miR-21 at 60 
nM were subjected to TUNEL assay. Cells were 
seeded into 6 well-plates containing cover slips 
at 4 × 104 cells/well, transfected with anti-
miR-21 at 60 nM for 24 hours and then treated 
Figure 1. A: Expression of miR-21, miR-
7, miR-124 e miR-137 in 9 pGBMs, cal-
culated as 2-∆∆Ct; REF, FirstChoice® 
Human Brain Reference Total. B: Ex-
pression of miR-21 in adult and pediat-
ric GBMs. 
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with Dox. TUNEL analysis was performed after 
72 hours of Dox treatment and the results were 
analyzed by fluorescence microscopy, as des- 
cribed above. All experiments were performed 
in triplicate.
Statistical analysis 
Data were expressed as mean ± SD. Statistical 
analysis of in vitro drug assays was performed 
by using the one-way ANOVA test and post hoc 
Bonferroni-corrected t-test on the software ver-
sion Graph Pad Prism 5.00. A level of p < 0.05 
was accepted as statistically significant. 
Statistical analysis of expression studies of 
adult and pediatric GBMs was performed by 
using the t-test and/or Levene test and the U 
Mannwhite test on the software package 
SPSS19.
aGBMs, with 4× lower values in the pediatric 
than in the adult tumors (P < 0.001, t-test) rela-
tive to calibrator FirstChoice ® Human Brain 
Reference Total (Figure 1B).
miRNA expression in U87MG, A172 and T98G 
cell lines
In order to evaluate the effect of Dox treatment 
on miR-21, miR-7, miR-124, miR-128 and miR-
137 expression, we treated U87MG, A172 and 
T98G cell lines with the chemotherapeutic 
agent at 0.834 µg/ml (0.1 × PPC for A172) and 
8.34 µg/ml (1 × PPC, for T98G and U87MG). 
Subsequently, we measured miRNA levels at 
different time points (12, 24 and 48 hours) 
after treatment. 
We observed low endogenous or no expression 
of miR-7, miR-124, miR-128 and miR-137 in 
A172, U87MG, and T98G treated and untreat-
Figure 2. qRT-PCR analysis of miR-21 expression levels (mean ± SD) in A172, 
U87MG and T98G cell lines treated with Dox (12, 24 and 48 h). b: untreated 
cells; t: treated cells. *p < 0.05; **p < 0.001; ***p < 0.0001.
Results 
miRNA expression in pediatric 
and adult glioblastomas 
Analysis of the series of 9 
pGBMs and 4 aGBMs showed 
an overlapping expression pa- 
ttern for all 5 miRNAs investi-
gated, characterized by over-
expression of miR-21 and re- 
duced or lack of expression of 
miR-7, miR-124, miR-128 and 
miR-137. 
The results of miRNA assays 
of the 9 pGBMs were com-
pared to two different refer-
ence samples, FirstChoice® 
Human Brain Reference Total 
and pediatric non-tumoral ce- 
rebral cortex. Both analyzes 
yielded the same results. Diff- 
erences in expression levels 
of 4/5 miRNAs were observed 
among the pGBM sample. This 
is likely due to cell heterogene-
ity in the samples (Figure 1A). 
No expression of miR-128 was 
detected.
We found that the expression 
of miR-21 was significantly dif-
ferent between pGBMs and 
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ed cells (data not shown). In contrast, our data 
demonstrated that there was a dynamic change 
in miR-21 expression after Dox treatment in all 
cell lines. miR-21 was overexpressed in untreat-
ed A172, U87MG and T98G cells, while only low 
basal expression was found after Dox treat-
ment (Figure 2). 
Dox sensitivity of GBM lines
Chemosensitivity was evaluated in three GBM 
cell lines treated for 24 and 48 hours with 0.1 
and 0.5 µg/ml of Dox (Figure 3). The lowest 
possible concentrations that achieved the most 
significant results were chosen as the optimal 
dosage. No statistically significant difference 
was observed after 24 hours of treatment 
between either U87MG or T98G vs control, 
while A172 exhibited a statistically significant 
difference at both Dox concentrations used 
(OD values 0.6 ± 0.23 for 0.1 µg/ml Dox, and 
0.6 ± 0.3 for 0.5 µg/ml Dox, respectively) vs 
control (OD 0.8 ± 0.2) (P < 0.05) (Figure 3A). 
Figure 3B illustrates the cytotoxic effect of Dox 
Figure 3. Cytotoxicity responses of A172, U87MG and T98G, after 24 (A) and 48 h (B) of Dox treatment, measured 
as OD by the MTT assay. C: TUNEL assay on A172, U87MG and T98G cell lines treated with 0.5 µg/ml Dox.
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at 48 hours of treatment and demonstrates 
that A172 and U87MG were sensitive at 0.1 
and 0.5 µg/ml concentrations, while T98G 
appeared to be resistant. OD values in A172 
were 0.7 ± 0.1 and 0.14 ± 0.06, respectively, vs 
control 1.11 ± 0.1 (P < 0.01); OD values in 
U87MG were 0.65 ± 0.1 and 0.3 ± 0.005, 
respectively, vs control 0.8 ± 0.02 (P < 0.001). 
OD values did not significantly differ between 
T98G treated and untreated cells. Our MTT 
experiments demonstrated that the most effec-
tive cytotoxic Dox dosage was 0.5 µg/ml. Based 
on these results, we performed a TUNEL assay 
to investigate the pro-apoptotic effects of 0.5 
µg/ml of Dox. This dosage induced apoptosis in 
A172 and U87MG but not in T98G, confirming 
that T98G is a drug resistant cell line (Figure 
3C).
miR-21 inhibition in T98G cells
To investigate whether miR-21 regulation influ-
ences the drug resistant phenotype, we trans-
fected anti-miR-21 into the T98G resistant cell 
line. To achieve the optimal effect of silencing 
with minimal off-target effects, different inhibi-
tor concentrations (from 10 to 160 nM) were 
tested. We found that transfection with miR-21 
inhibitor reduced miR-21 expression in a dose 
dependent manner (Figure 4A). The 60 nM con-
ml. TUNEL analysis was performed after 72 
hours of Dox treatment. 
The data show that miR-21 inhibition in associ-
ation with Dox treatment leads to increased 
apoptosis in T98G Dox-resistant cells (Figure 
5A). In contrast, few apoptotic cells were 
observed in the corresponding cells treated 
with miR-21 inhibitor or Dox alone (Figure 5B, 
5C). Figure 5D demonstrates that the treat-
ment with miR-21 inhibitor (overall 96 hours) 
plus Dox (for 72 hours) resulted in a significant 
23% increase in the apoptotic rate when com-
pared with Dox treatment alone (Figure 5D). 
Based on these results, we tested the chemo-
sensitivity of GBM cells treated with miR-21 
inhibitor plus Dox by the MTT assay (Figure 5E). 
The data show that only the concomitant use of 
miR-21 inhibitor and Dox is effective in inhibit-
ing the growth of T98G cells. While treatment 
with miR-21 inhibitor or Dox alone has no effect, 
the viability of T98G cells was largely reduced 
when the two substances were used in 
combination. 
Our data suggest that combined Dox and miR-
21 inhibitor therapy can sensitize GBM resis-
tant cells to anthracyclines by enhancing apo- 
ptosis.
Figure 4. A: Transfection with miR-21 inhibitor reduces miR-21 expression in 
T98G cells in a dose dependent manner. BC is a blank transfection control 
used in comparative CT-fold change analysis. B: Levels (mean ± SD) of miR-
21 expression in the T98G cell line before (T98G-P) and after transfection 
(T98G-T) with miR-21 inhibitor assessed by qRT-PCR. *p < 0.05.
centration gave the maximal 
effect and resulted in approxi-
mately 80% decrease in miR-
21 expression. 
The inhibitory effect of anti-
miR-21 at 60 nM was assess- 
ed by qRT-PCR 48 hours after 
transfection. Our data showed 
that the expression level of 
miR-21 was significantly lower 
in T98G transfected cells 
(T98G-T) than in the parental 
cells (T98G-P) (Figure 4B).
Effects of concomitant Dox 
treatment and miR-21 inhibi-
tion 
In order to test whether miR-
21 inhibition improves the 
response of Dox-resistant ce- 
lls to Dox re-challenge, T98G 
cells were transfected with 
anti-miR-21 for 24 hours and 
then treated with Dox 0.5 µg/
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Discussion
In this study, in order to identify miRNAs that 
are involved in the pathogenesis and develop-
ment of pediatric and adult high grade gliomas, 
we first used quantitative RT-PCR to analyze 
the expression of 5 miRNAs that had previously 
been found to be dysregulated in GBMs sam-
ples [18, 26]. miR-21 was overexpressed in all 
9 pGBM samples investigated, while the ex- 
Figure 5. TUNEL assay, showing apoptotic nuclei in green. A: miR-21 inhibitor plus Dox. B: miR-21 inhibitor alone. C: 
Dox alone. D: Increased apoptotic rate after concomitant treatment with miR-21 inhibitor 60 nM and Dox 0.5 µg/ml 
(**p < 0.01). Bar chart shows the percentage (mean ± SD) of apoptotic cells counted from three randomly selected 
view fields. E: Cytotoxicity response of T98G cells transfected with miR-21 inhibitor 60 nM (96 h) and treated with 
Dox 0.5 ug/ml (72 h). Data are presented as mean ± SD (error bar). ***p < 0.001 inhibitor plus Dox vs control.
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pression of miR-7, miR-124, miR-128 and miR-
137 was either reduced or absent. Interestingly, 
we detected a significant difference between 
pGBMs and aGBMs, since the former showed a 
4X lower degree of miR-21 expression com-
pared to the latter (p = 0.001).
Anthracyclines such as Dox are commonly used 
in the treatment of a wide range of tumors, 
including hematological malignancies, many 
types of carcinoma and soft tissue sarcomas 
[31].  Data on in vitro and in vivo malignant gli-
oma models suggest that Dox can be effective 
for these tumors [32-34]. Eramo and co-work-
ers have demonstrated that Dox displays high 
antitumor activity against GBM stem cells [35].
In order to evaluate the cellular response to 
anthracyclines in glioblastoma we used three 
GBM cell lines (A172, U87MG and T98G), iden-
tifying a different behaviors among them. In 
fact, a cytotoxic effect was observed in A172 
and U87MG after 48 hours of Dox treatment 
while T98G cells appeared to be resistant to 
the drug. This was confirmed by the finding of 
apoptosis induction following Dox treatment in 
A172 and U87MG, but not in T98G. 
On the same cells we analyzed the expression 
of the 5 miRNAs described above; only miR-21 
exhibited a different expression level in all cell 
lines with or without Dox treatment. 
To validate the possible association of miR-21 
with drug resistance of T98G cells, we investi-
gated the effects of a specific miR-21 inhibition 
on the cells. The data showed that the expres-
sion level of miR-21 was significantly lower in 
T98G transfected cells (T98G-T) than in the 
parental control cells (T98G-P); moreover, the 
transfected cell line showed a high apoptotic 
rate compared to the control after Dox treat- 
ment.
Our results suggest that combined Dox and 
miR-21 inhibitor therapy may regulate anthracy-
clines resistance via augmented apoptotic 
pathway.
Different signal transduction pathways seem to 
be involved in the chemoresistance mecha-
nisms of GBMs. miRNAs are candidate modula-
tors of the response to antineoplastic agents of 
these malignant tumors. miRNA expression has 
been investigated in pediatric malignant brain 
tumors, including GBM, using microarray ex- 
pression profiling. Pediatric CNS tumors exhib-
ited tumor-specific miRNA signatures and dif-
ferential miRNA expression (miR-129, miR-142-
5p, and miR-25) compared to normal brain [19, 
20]. Moreover, some miRNAs have been shown 
to down-regulate the levels of proteins involved 
in key pathways downstream of tyrosine kinase 
signaling in adult GBM [18].
miR-21, an oncomiR, plays a crucial role in a 
plethora of biological functions and diseases 
including development, cancer and inflamma-
tion. miR-21 is one of the most investigated 
miRNAs in human cells, and its expression is 
significantly up-regulated in several tumors. 
miR-21 expression has been correlated with 
tumor grade and has been proposed as a mark-
er of tumor progression [36, 37]. miR-21 regu-
lates a nuclear complex including AP-1/b-ca- 
tenin [38] and also plays a role in the response 
to anti-EGFR treatment through modulation of 
the EGFR signaling pathway [38]. 
Original experiments demonstrated that miR-
21 is frequently up-regulated in human GBM 
and that its inhibition leads to caspase stimula-
tion and associated apoptotic cell death in dif-
ferent GBM cell lines [39]. In addition, miR-21 
seems to contribute to tumorigenicity and inva-
sion of glioma cells through targeting the com-
ponents of the p53 and TGF-b pathways, mito-
chondrial apoptosis-related genes, as well as 
RECK and TIMP3 [22, 40].
Importantly, it has been shown that down-regu-
lation of miR-21 can inhibit the growth of GBM 
cell lines and induce apoptosis independently 
of PTEN status. These observations were con-
firmed in in vivo xenografts, highlighting the 
potential clinical relevance of miR-21-targeting 
agents [41]. Recently, miR-21 was also shown 
to regulate PDCD4, a tumor suppressor gene, in 
GBM cells [42]. GBM-derived cell lines treated 
with anti-miR-21 had reduced proliferation and 
also exhibited enhanced apoptosis, compared 
with untreated controls. In addition, cell lines in 
which miR-21 levels were inhibited displayed 
decreased anchorage-independent growth, wh- 
ereas GBM-derived cell lines expressing PDCD4 
showed increased apoptosis and diminished 
anchorage-independent growth [43].
miR-21 seems to regulate drug resistance in 
various cancers, and therefore the use of miR-
21 inhibitors may function as an effective 
approach for reversing drug resistance in can-
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cer cells. High levels of miR-21 are a common 
feature of GBM, and it has been shown that it 
can function as an anti-apoptotic factor in cul-
tured GBM cells [39]. It has already been dem-
onstrated that up-regulation of miR-21 can 
induce Dox chemoresistance in T24 human 
bladder cancer cells while down-regulation of 
miR-21 sensitized T24 cells to the drug [44]. 
Likewise, miR-21 blockage increased the che-
mosensitivity of human GBM cells to Taxol. 
Furthermore, down-regulation of miR-21 incr- 
eased the chemosensitivity of glioma cells to 
Etoposide [45]. The concomitant use of miR-21 
inhibitors and antineoplastic drugs could there-
fore be an effective therapeutic strategy for 
suppressing the growth of GBM, regardless of 
PTEN status [46].
Treatment of glioma cells with anti-miR-21 did 
not cause any change in proliferative capacity, 
although it resulted in significant reduction of 
the ability to form colonies in soft agar, further 
suggesting that this miRNA might play an 
important role in neoplastic transformation 
[45]. 
In conclusion, our study provides evidence that 
miR-21 inhibition in addition to pharmacologi-
cal treatment could pave the way to new effec-
tive approaches for reversing drug resistance in 
GBM. Further studies are warranted to better 
understand how miRNAs can be explored as a 
potential chemotherapy adjunct in the treat-
ment of resistant brain tumors.
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